{"id":"NCT01544179","sponsor":"AstraZeneca","briefTitle":"A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","officialTitle":"A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progressed on First Line IRESSA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03-15","primaryCompletion":"2014-05-05","completion":"2019-11-20","firstPosted":"2012-03-05","resultsPosted":"2016-02-15","lastUpdate":"2020-09-25"},"enrollment":265,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Gefitinib","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]}],"arms":[{"label":"Gefitinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of gefitinib in patients who have progressed on first line gefitinib, comparing continuing gefitinib in addition to cisplatin plus pemetrexed combination chemotherapy versus cisplatin plus pemetrexed combination chemotherapy alone.","primaryOutcome":{"measure":"Progression-Free Survival (Site Read, Investigator Assessment)","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis, assessed up to 50 weeks","effectByArm":[{"arm":"Gefitinib","deltaMin":98,"sd":null},{"arm":"Placebo","deltaMin":107,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.273"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":61,"countries":["China","France","Germany","Hong Kong","Hungary","Italy","Japan","Russia","South Korea","Spain","Taiwan"]},"refs":{"pmids":["26159065"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=612&filename=D791LC00001_CSR_Synopsis.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=612&filename=D791LC00001REDACTED_PROTOCOL.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":132},"commonTop":["Nausea","Decreased appetite","Vomiting","Anaemia","Constipation"]}}